A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2027

Conditions
Moderate to Severe Genital Psoriasis
Interventions
DRUG

Tildrakizumab 100 mg

Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter

DRUG

Placebo

Placebo SC injection at Day 1 and Week 4

Trial Locations (62)

144

JSC Curatio, Tbilisi

159

New Vision Univestiry Hospital, Tbilisi

160

Aversi Clinic, Tbilisi

179

David Abuladze Clinic (DAC), Tbilisi

186

Raymann, Tbilisi

1463

Medical Centre Regina Life Clinic, Sofia

1527

UMHAT Tsaritsa Yoanna-ISUL, Sofia

1528

Diagnostic Consulatative Center, Sofia

5000

Allergo-Derm Bakos Kft, Baross U 20.

5500

MC Medconsult-Lovech, Lovech

5800

Medconsult Pleven, Pleven

10023

Equity Medical, New York

11415

Forest Hills Dermatology, Kew Gardens

27104

Wake Forest University Health Sciences, Winston-Salem

27401

The Moses H. Cone Memorial Hospital Operating Corporation, Greensboro

28105

Javara Inc/ Tryon Medical Partners, PLLC, Matthews

28602

Hickory Dermatology Research Center, LLC, Hickory

30305

Dermatology Affiliates Research Institute, LLC, Atlanta

31792

Mcintosh Clinic, PC, Thomasville

33033

Homestead Associates in Research Inc, Homestead

33134

Coral Gables Dermatology & Aesthetics, Coral Gables

Florida Academic Centers Research and Education, LLC, Coral Gables

33157

Genomics Medical Research, Miami

33165

Med-Care Research, Miami

37072

Goodlettsville Dermatology Research, Goodlettsville

37211

Advanced Research Experts, Nashville

44512

The Indiana Clinical Trials Center Optima Research Boardman, Boardman

46168

The Indiana Clinical Trials Center, Plainfield

48326

Oakland Hills Dermatology PC, Auburn Hills

49316

The Derm Institute of West Michigan, Caledonia

68144

Skin Specialists, PC, Omaha

76011

Arlington Research Center, inc., Arlington

77004

Center for Clinical Studies, LTD. LLP, Houston

77598

Center for Clinical Studies, LTD. LLP, Webster

78213

Progressive Clinical Research, San Antonio

78218

Texas Dermatology and Laser Specialists, San Antonio

80033

Paradigm Clinical Research, Wheat Ridge

85006

Medical Dermatology Specialists, Phoenix

90045

Dermatology Research Associates, Los Angeles

90057

LA Universal Research Center Inc, Suite 1, Los Angeles

90404

Dermatology Institute and Skin Care Center, Inc. DBA Clinical Science Institute, Santa Monica

91324

Amicis Research Center, Northridge

91436

T. Joseph Raoof MD, Inc./Encino Research Center, Encino

92024

California Dermatology & Clinical Research Institute, Encinitas

92123

Therapeutics Clinical Research, San Diego

92806

Smary Cures Clinical Research, Anaheim

94538

Center for Dermatology Clinical Research, Inc, Fremont

97201

Oregon Medical Research Center, Portland

98004

James Song, MD (James Song), Bellevue

H-4032

University of Debrecen Dept of Dermatology, Debrecen

51-503

Niepubliczny Zakladu Opieki Zdrowotnej MultiMedica s.c., Wroclaw

20-573

Luxderm Specjalistyczny Gabinet Dermatologiczny, Lublin

30-033

Centrum Medyczne \All-Med\ spolka komandytowa, Krakow

35-055

Uniwersytecki Szpital Kliniczny, Klinika Dermatologii, Rzeszw

82-200

"Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o.o", Malbork

15-351

Zdrowie Osteo-Medic s.c., Bialystok-Podlaskie

80-546

Care Access Gdansk, Gdansk

40-600

Care Access Holsamed Katowice, Katowice

30-438

Lidia Rajzer-Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, Krakow

20-011

Clinical Best Solution Sp. z o.o Sp. k. w Lublinie, Lublin

00-710

Clinical Best Solutions SP. Z.O.O. SP.K., Warsaw

02-953

Klinika Ambroziak, Warszswa

All Listed Sponsors
lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT06611163 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. | Biotech Hunter | Biotech Hunter